Wegovy cut heart attacks by 20% 🧬

LONGEVITY LATEST ISSUE 12 · 27 MAY 2026

LONGEVITY LATEST

The Evidence-Based Edge on Living Longer and Better

Issue 12 · GLP-1: The Weight-Loss Drugs That Turned Into Heart Drugs · 27 May 2026

WELCOME

👋 Welcome

A heart-disease trial reported two years ago that nobody quite knew how to file. It cut major cardiac events by a fifth — heart attacks, strokes, cardiovascular deaths — in seventeen thousand people who didn't have diabetes. The drug was semaglutide, the molecule the internet files under "skinny jab."

Here's the puzzle that's driven two years of speculation: the cardiac benefit showed up earlier than the weight loss can explain, and tracked a 40% drop in an inflammation marker more closely than the pounds. So the question underneath this whole issue is simple — are these drugs treating obesity, or treating ageing itself? This week a clean test of that question finally reported, and the answer reframes everything below. It's the spine of today's Deep Dive.

In this issue:

• 🔬 Top 3: Semaglutide, tirzepatide, retatrutide — graded on hard outcomes, not headlines

• ⭐ Spotlight: The muscle you lose with the fat — and who actually needs to worry

• 🚨 Hype Check: Compounded "research" GLP-1 — the £200 vial after the shortage ended

• 📖 Deep Dive: Are these obesity drugs, or ageing drugs? The test that just settled it

• 🌾 Superfood: Oats — the closest thing to a GLP-1 you can eat

• 🌡 Biohacking Corner: Which reader are you — and what to actually do

THIS WEEK'S ANALYSIS

🔬 Top 3 Interventions Under the Microscope

Three drugs, three points on the evidence curve: one with hard-outcome proof, one with more firepower but a pending verdict, one that isn't approved anywhere yet. Grade accordingly.

1. Semaglutide (Wegovy / Ozempic) — Evidence Grade: A

What it is. A once-weekly GLP-1 receptor agonist — it mimics a gut hormone released when you eat, slowing stomach emptying, blunting appetite, and improving how the pancreas handles glucose. The most-studied molecule in the class.

Human evidence. This is the one with the hard-outcome trial behind it. SELECT (Lincoff et al., NEJM 2023) randomised 17,604 adults with overweight or obesity and established cardiovascular disease — crucially, no diabetes — to semaglutide 2.4 mg or placebo for about three years. Major adverse cardiovascular events fell 20% (6.5% vs 8.0%; HR 0.80). That's a hard endpoint — heart attack, stroke, cardiovascular death — not a surrogate. And here's the part that made me sit up: weight loss averaged only ~9%, the event curves separated earlier than that can explain, and high-sensitivity CRP dropped close to 40%. The kidney trial (FLOW, NEJM 2024) pointed the same way — a 24% reduction in major kidney events. The benefit looks bigger than the bathroom scale.

Cautions. Nausea is common early and fades with slow titration. Contraindicated with a personal or family history of medullary thyroid carcinoma or MEN2. Pancreatitis history needs a real conversation with a prescriber, and combined with insulin or a sulfonylurea it can drop blood sugar too far. Not a tool for a normal-BMI body chasing a flatter stomach.

Takeaway. Large RCTs, hard endpoints, consistent direction — for the licensed metabolic and cardiovascular indications, this is as good as the evidence gets. Evidence Grade A.

2. Tirzepatide (Mounjaro / Zepbound) — Evidence Grade: B+

What it is. A dual agonist hitting both the GLP-1 and GIP receptors — which in practice means more weight loss than semaglutide head-to-head. It's the one your gym's WhatsApp group keeps mentioning.

Human evidence. The efficacy is striking: SURMOUNT-1 (NEJM 2022, n=2,539) produced up to 22.5% body-weight reduction at 72 weeks — numbers that used to need surgery. The breadth is what elevates it past a slimming drug: SURMOUNT-OSA (NEJM 2024) roughly halved the apnoea–hypopnoea index, earning an FDA sleep-apnoea approval in late 2024, and SUMMIT (NEJM 2024) cut cardiovascular death or worsening heart failure by 38% in HFpEF with obesity.

Cautions. Same GI and thyroid/pancreatitis flags as semaglutide, a touch more intense at top doses. Faster, deeper loss makes the muscle question (below) more pressing, not less.

Takeaway. Probably the most effective metabolic drug we have — but the one trial that would settle it, a dedicated cardiovascular-mortality outcomes trial, hasn't reported yet. Surrogate wins everywhere, one pending answer on the question that matters most. Evidence Grade B+, and I'd revise it up the day the mortality data lands.

3. Retatrutide — Evidence Grade: C+

What it is. The next escalation: a triple agonist adding the glucagon receptor to GLP-1 and GIP. Glucagon sounds backwards in a weight drug — it raises blood sugar — but it also lifts energy expenditure.

Human evidence. Fair warning before the number: this is a single phase 2 trial. With that said, Jastreboff et al. (NEJM 2023, n=338) reported 24.2% mean weight loss at 48 weeks on the top dose, and the curve hadn't flattened. If it holds in phase 3 (TRIUMPH, enrolling now), it's the largest pharmacological weight loss yet recorded.

Takeaway. The most exciting molecule in the class and the least proven — one mid-sized trial, a surrogate endpoint, no outcomes data, no approval anywhere. We've watched too many drugs dazzle at phase 2 and stumble later. Evidence Grade C+: watch it, don't chase it.

SPOTLIGHT

⭐ Spotlight Treatment: The Muscle You Lose With the Fat

Every weight-loss method costs you some lean mass — that's physiology, not a drug flaw. Lose weight by any route and a quarter to a third comes from fat-free tissue. The honest questions are whether GLP-1s make that worse, and who it actually matters for.

I went in braced for a scare story. It's more nuanced. In the STEP-1 body-composition substudy, around 40% of the weight lost on semaglutide was lean mass — higher than some hoped, but roughly what fast weight loss does generally. For a 45-year-old with obesity, that's mostly fine: the fat being shed is the metabolically dangerous kind, and grip strength and function held in the trials that measured them.

The real concern is narrower than the headlines. It's the 75-year-old who's already sarcopenic, or the lean older adult without much muscle to spare. Strip lean mass off them fast and you can trade a metabolic problem for a frailty one — and frailty kills.

Pros

✓ The fat being lost is the dangerous visceral kind; measured function held up.

✓ Muscle loss is largely preventable — adequate protein plus resistance training shifts the loss heavily toward fat.

✓ Muscle-sparing combinations (semaglutide plus bimagrumab pushed ~93% of loss to fat vs ~72% alone) are in trials.

Cons

⚠ In frail or sarcopenic older adults, rapid lean-mass loss is a real downside, not a theoretical one.

⚠ The muscle-sparing add-ons are early — promising, unapproved, not yet something to plan around.

⚠ Almost nobody has the protein-and-lifting conversation at the point of prescription, which is exactly when it should happen.

The drug takes the weight off either way. Whether it comes off as mostly fat or partly strength is the one variable still in your hands.

HYPE CHECK

🚨 Hype Check: Compounded "Research" GLP-1

The Hype. For two years, telehealth sites and "research peptide" resellers sold compounded semaglutide and tirzepatide at a fraction of the brand price — often £150–£250 a month, sometimes as multidose vials you draw up yourself. While the brands were officially in shortage, compounding them was legal.

The Evidence. That window has closed. The FDA declared the tirzepatide shortage resolved in October 2024 and semaglutide in February 2025, with enforcement deadlines through spring 2025 ending mass compounding from bulk substance. Why it matters for your body, not just the lawyers': by early 2025 the FDA had logged over 455 adverse-event reports tied to compounded semaglutide and 320-plus for tirzepatide — a meaningful share of them dosing errors, people drawing the wrong amount from a multidose vial and ending up in hospital. Some were tenfold overdoses. Sit with that for a second — it's the self-injection problem we mapped in the Grey Peptide Economy Deep Dive (Issue 09), now with a drug potent enough that a measurement slip puts you in A&E.

Why It's Misleading. "Same active ingredient" does enormous work in that sentence. The molecule might be right. The dose in the syringe, the sterility of the vial, and the legality of the seller are three separate gambles — and post-shortage, that seller is increasingly one the FDA is issuing warning letters to.

DEEP DIVE

📖 Deep Dive — Are These Obesity Drugs, or Ageing Drugs?

This is the question the whole issue has been circling, and a clean test of it just reported.

If GLP-1s work upstream of obesity — on inflammation, the vasculature, the brain — the boldest prediction was that semaglutide would slow Alzheimer's. The EVOKE and EVOKE+ trials (The Lancet, 2026; 3,808 people with early Alzheimer's) tested exactly that. The result: no slowing of cognitive decline at two years. The spinal-fluid biomarkers moved a little. The disease didn't.

That single negative tells you more than a dozen excited podcasts. The companion piece is the verdict to this issue's evidence tour — it walks the SELECT inflammation signal that started the speculation, what "weight-independent benefit" really means, why the Alzheimer's failure matters, and the honest line between treating ageing and treating the diseases ageing causes.

👉 Read this next — it's the point of the issue: The Weight-Loss Drug That Cut Heart Attacks — and Failed at Alzheimer's

SUPERFOOD

🌾 Superfood Spotlight: Oats

A breather from the pharmacology — and, conveniently, the same hormone in food form. Oats are unusually rich in beta-glucan, a soluble fibre that thickens in the gut, slows stomach emptying, and in controlled trials nudges your own GLP-1 secretion. Gently, not pharmacologically — but in the right direction.

A randomised crossover trial (Rebello et al., Nutrition Journal) found oat beta-glucan at breakfast raised fullness and GLP-1 versus a matched control; a 2024 crossover study confirmed slower gastric emptying from beta-glucan-enriched oat bread. Honest caveat: the effect on how much people actually eat later is modest and inconsistent. It's also the best-evidenced cholesterol-lowering food we have. Aim for 40g of porridge oats with the beta-glucan intact — steel-cut or rolled, not the instant sugary sachets. A kilo costs about £1.30, roughly a hundredth of the monthly drug.

BIOHACKING CORNER

🌡 Biohacking Corner: Which Reader Are You?

Most of the GLP-1 noise comes from one-size-fits-all advice. Find yourself first, then act:

• Obesity with CVD, diabetes, sleep apnoea, or heart failure? The evidence is squarely on your side. The decision is which drug and which prescriber, not whether.

• Frail or lean and over ~70? Muscle preservation comes first. Have the lean-mass conversation before the prescription, not after.

• A lean optimiser chasing these for "anti-ageing"? Read the Deep Dive — the EVOKE result is your reality check.

• Tempted by a grey-market vial? Re-read the Hype Check. The shortage is over; the safe route exists.

Whatever bracket you're in, if weight is coming off, the protocol that protects muscle is the same — and mostly free. A 2024 meta-analysis confirmed it: resistance training plus adequate protein shifts loss toward fat and away from muscle.

1. Protein first, every meal — 1.6 g per kg of goal body weight, front-loaded. Appetite is suppressed, so protein has to win the limited room. A 90kg person aiming for 75kg wants ~120g a day.

2. Lift twice a week, minimum — compound movements, real load. This is the single biggest lever on whether weight leaves as fat or strength. Cardio is good for you; it doesn't preserve muscle the way load does.

3. Don't crash the dose — slower titration means a better fat-to-lean ratio and far less nausea. Patience is muscle-sparing.

READER PULSE

📊 Reader Pulse

Last issue's hormone poll drew our second-highest turnout: about a third of you on TRT or HRT through a mainstream prescriber, just under a fifth through a private optimisation clinic, and a striking quarter "considering it — gathering information." That considering-it quarter is exactly who the pellet clinics target, which is why Issue 11 named names.

🎯 Closing

The discipline here is the same as ever: grade on the hard outcomes, protect the muscle, and don't inject anything measured by eye. But the sharper lesson is the one the Deep Dive lands — these are superb cardiometabolic drugs and unproven ageing drugs, and the gap between those two things is where money gets wasted and risks get taken.

Issue 13 turns the microscope on a person rather than a molecule: the Bryan Johnson "Blueprint" stack, audited pill by pill. Which of the 70-odd daily capsules have evidence behind them, which ride a single mouse study, and what a £4 supermarket multivitamin actually buys you versus a £400 personalised stack. Plus a Hype Check on the consumer epigenetic age tests now telling people they're "biologically 38."

Stay curious and stay healthy!

— Christian Thomsen, Editor

Longevity Latest is published weekly by FrontWave Media Ltd. The content is for educational purposes and does not constitute medical advice. GLP-1 receptor agonists are prescription medicines that require individualised assessment. Consult your physician before starting, stopping, or changing any medication — particularly if you are pregnant, nursing, have a personal or family history of medullary thyroid carcinoma or MEN2, a history of pancreatitis, or take insulin or a sulfonylurea.

© 2026 FrontWave Media Ltd · Longevity Latest